Veru Inc. Earnings Call Transcripts
Fiscal Year 2026
-
Enobosarm, combined with GLP-1, aims to address muscle loss and functional decline in older obese patients, with Phase 2b studies showing promising results in lean mass preservation and fat loss. The upcoming Plateau study targets regulatory approval through multiple endpoints, with top-line data expected in Q4 2027.
-
Net loss narrowed to $5.3M as R&D and admin costs declined, with $33M in cash supporting operations through the next clinical milestone. Positive phase II-B results and FDA feedback advance enobosarm's development for obesity, targeting selective fat loss and muscle preservation.
Fiscal Year 2025
-
Positive Phase 2b results for enobosarm showed preserved lean mass and enhanced fat loss in obese patients on GLP-1 therapy. Divestiture of the FC2 business and a public offering strengthened the financial position, supporting the upcoming PLATEAU trial targeting older, high-BMI patients.
-
Phase II-B data showed enobosarm + semaglutide preserved lean mass and enhanced fat loss in older adults with obesity, with a strong safety profile. Financials reflect a narrowed focus on drug development, reduced losses, and the need for additional capital to fund Phase III trials.
-
Phase IIB results showed Enobosarm plus semaglutide preserves lean mass and enhances fat loss in older obese patients, with positive safety signals and key regulatory and clinical catalysts expected this quarter. Cash runway extends into Q4 2025, but additional funding will be needed for phase III.
-
Reported positive phase II-B results for enobosarm, showing significant lean mass preservation and fat loss in older obese patients on GLP-1 therapy. Sold FC2 business to focus on biopharma, improving financial flexibility but requiring additional capital for future operations.
-
Enobosarm, combined with semaglutide, preserved muscle mass and improved function in older patients, meeting key endpoints in a phase II-B study. The company is advancing to phase III with a new oral formulation, targeting a large, underserved market and maintaining strong IP protection.
-
The Phase IIb QUALITY study showed enobosarm significantly preserved lean mass and increased fat loss in older adults on GLP-1 therapy, with improved physical function and no new safety concerns. Both 3 mg and 6 mg doses were effective, with 3 mg likely preferred for phase 3.
Fiscal Year 2024
-
GLP-1 weight loss drugs cause significant muscle loss, especially in older adults, leading to functional and metabolic issues. Enobosarm, a selective androgen receptor modulator, is being tested to preserve muscle and improve function in combination with GLP-1s, with pivotal trial data expected in early 2025.
-
Q3 2024 saw higher revenues and reduced losses, driven by growth in global public sector sales and lower expenses. The Phase 2b QUALITY trial for enobosarm in weight loss is fully enrolled, with top-line results expected in January 2025.
-
Leadership transition is underway as the company leverages a decade-long transformation into life sciences, focusing on integration, margin improvement, and strategic growth. China and consumables drive robust performance, while B Medical and cross-selling initiatives support future profitability.